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ABSTRACT The past decade has witnessed huge
advances in our understanding of the genetics underly-
ing Parkinson’s disease. Identifying commonalities in
the biological function of genes linked to Parkinson’s
provides an opportunity to elucidate pathways that lead
to neuronal degeneration and eventually to disease. We
propose that the genetic forms of Parkinson’s disease
largely associated with -synuclein-positive neuropa-
thology (SNCA, LRRK2, and GBA) are brought to-
gether by involvement in the autophagy/lysosomal
pathway and that this represents a unifying pathway to
disease in these cases.—Manzoni, C., Lewis, P. A.
Dysfunction of the autophagy/lysosomal degradation
pathway is a shared feature of the genetic synucleinopa-
thies. FASEB J. 27, 3424–3429 (2013). www.fasebj.org
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Parkinson’s disease (PD) is a neurodegenerative dis-
order characterized by the preferential death of dopa-
minergic neurons. Historically, PD has been defined
histopathologically by two key features: the loss of
neurons in the substantia nigra pars compacta and the
presence of intracellular proteinaceous inclusion bod-
ies called Lewy bodies (LBs) (1). The major advances in
the field of medical genetics during the 1980s and
1990s opened a new chapter in the study of PD by
facilitating the identification of genes linked to mende-
lian forms of this disease, starting with SNCA, coding for
-synuclein, in 1997 (2). Both point mutations and
gene multiplications in -synuclein are causative for
familial PD (3). The association of -synuclein with
inherited parkinsonism led, in turn, to an important
breakthrough in the classification of the pathology of
PD with the realization that the neuropathological
hallmark of this disease, the LB, was made up of
aggregates of -synuclein (4).
FOLLOWING THE PATHOLOGY
A number of other genes have subsequently been
identified in familial forms of PD (Table 1), the most
common of which are mutations in the LRRK2 gene on
chromosome 12, coding for leucine-rich repeat kinase
2 (LRRK2) (5). Dominant mutations in LRRK2 cause a
parkinsonian syndrome clinically similar to sporadic
PD. Although the majority of cases (90%) present
with LB pathology, a significant minority of cases
manifest with Tau, A, TDP-43, or ubiquitin-positive
inclusions in the absence of LBs (6).
Homozygous mutations in GBA, encoding glucocer-
ebrosidase (GBA), cause Gaucher’s disease (GD), a
lysosomal storage disorder. It has long been noted that
a subset of patients with GD present with parkinsonism,
and this clue has led recently to the realization that
individuals with a mutation in the heterozygous state
have an increased risk of developing PD, with abundant
LB pathology (7).
In addition to SNCA, LRRK2, and GBA, a number of
other inherited parkinsonian syndromes have been
identified, most notably those linked to mutations in
PARK2 (coding for parkin), PINK1, and PARK7 (coding
for DJ-1). These disorders are inherited in an auto-
somal recessive manner, with the protein products of
PARK2 and PINK1 localized to a common pathway
involved in mitochondrial quality control (8). PARK7
has been implicated in a number of cellular processes,
including the response to oxidative stress, RNA regula-
tion, and protein folding, and may act in a parallel
pathway to the parkin/PINK1 pathway (9, 10). The
relationship of these recessive disorders to the synucle-
inopathies is unclear. For PINK1 and PARK7, the
paucity of neuropathological reports makes it difficult
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to judge whether these are indeed LB disorders (11). A
number of PARK2 cases have come to autopsy, and
although a minority of cases present with LBs, it has
been suggested that these are secondary to the disease
process (12).
Finally, several genes have been recently associated
with parkinsonism. Mutations in vacuolar protein sort-
ing 35 (VPS35) cause a parkinsonian syndrome clini-
cally similar to sporadic PD (13, 14). Mutations in the
P5-type ATPase 13a2 (ATP13a2) are associated with a
clinical syndrome called Kufor-Rakeb. Although this
syndrome is clinically distinct from PD (it is character-
ized by pyramidal degeneration, widespread neurode-
generation, and dementia), one of the clinical features
is early-onset parkinsonism (15). There are no pub-
lished neuropathological reports for individuals har-
boring mutations in either of these genes, so it is not
known whether they are associated with -synuclein
aggregation and LB pathology. Notably, however, the
functions of both ATP13a2 and VPS35 have been the
subject of a number of studies that aid us in interpret-
ing how their dysfunction might lead to disease.
LOOKING FOR PATTERNS
One of the major benefits of identifying inherited
forms of disease is that this allows a systematic analysis
of pathways that are involved in a particular disorder.
An example of this is the realization that the 3 genes
linked to mendelian forms of Alzheimer’s disease (AD),
APP, PSEN1, and PSEN2, are all involved in the produc-
tion of the A peptide (16). The identification of this
pathway has led to a 20-yr effort to target the proteolytic
events leading to the production of A, resulting in the
identification of the secretases that cleave the A
precursor protein (APP), and to the development of
compounds to manipulate these proteolytic events.
This example highlights the utility of understanding
the links between different genes connected to the
same pathology.
In contrast to AD, grouping the inherited forms of
PD and parkinsonism has shown only limited success.
As noted above, PARK2 and PINK1 have been robustly
demonstrated to map to the same cellular pathway, but
how the other genes implicated in PD group together
into a pathogenic pathway or pathways is unclear. A
recent review suggested lysosomal dysfunction as a
unifying feature of PD (17). The hypothesis that we
propose here is that the genes associated with LB-
positive PD (SNCA, LRRK2, and GBA) are linked by a
common role in the autophagy/lysosomal pathway.
Based on phenotypic and cellular studies, we propose
that parkinsonism caused by mutations in VPS35 and
ATP13a2 also result from disruption of the autophagy/
lysosomal system.
EXAMINING THE SUSPECTS
The central player in genetic LB disorders is -sy-
nuclein. As such, this protein is the logical starting
point when examining the evidence supporting a com-
mon leitmotif linking the inherited synucleinopathies.
-Synuclein
-Synuclein is a 140-aa protein of unknown function
(3). Accumulating evidence shows that dysfunction of
-synuclein affects the autophagic pathway. Modulation
of synuclein protein levels inhibits autophagy via
Rab1a, and dominant mutations in -synuclein associ-
ated with PD can decrease lysosomal functionality, thus
reducing the flux through the autophagy pathway (18,
19). -Synuclein can also be degraded via chaperone-
mediated autophagy (CMA), a process disrupted by
mutations, which suggests that synuclein can take sev-
eral routes to degradation by the lysosomes (19, 20).
Abnormal accumulation of monomeric -synuclein
within the cell is likely to be the first step to misfolding
and aggregation, leading to deposition in LBs, and
dysfunction of degradation pathways will have a pro-
found effect on this process (3). In the context of the
hypothesis under discussion here, a potentially impor-
tant aspect of synuclein biology is its link to the
regulation of vesicle trafficking. Much of the data
relating to -synuclein function focuses on a role in the
regulation of SNARE proteins, which form multicom-
ponent complexes that are essential for vesicle fusion
events. In particular, -synuclein has been implicated
in synaptic vesicle fusion, highlighted by a study inves-
tigating a mouse lacking -, -, and -synucleins (21). It
is noteworthy that SNARE complexes are also required
for the correct function and fusion of autophagic
TABLE 1. Genetic synucleinopathies
Gene Protein Phenotype Pathology Inheritance Mutations
SNCA -Synuclein PD, DLB LB Dominant Point mutations (A53T, A30P, E46K, H50Q,
and G51D), gene multiplications
GBA GBA GD, PD LB Dominant Point mutations (numerous described, most
common L444P and N370S)
LRRK2 LRRK2 PD Pleiomorphic, mostly LB Dominant Point mutations (N1437H, R1441G/C,
Y1699C, G2019S, and I2020T)
ATP13a2 ATP13a2 KRS, NCL Unknown Recessive Truncations
VPS35 VPS35 PD Unknown Dominant Point mutation (D620N)
ATP13a2, ATPase 13a2; DLB, dementia with Lewy bodies; GBA, glucocerebrosidase; GD, Gaucher’s disease; KRS, Kufor-Rakeb syndrome;
LRRK2, leucine-rich repeat kinase 2; NCL, neuronal ceroid lipofuscinosis; SNCA, synuclein ; VPS35, vacuolar protein sorting 35.
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vesicles, which provides a potential link between the
physiological role of -synuclein and autophagy (22).
Whether the physiological function of -synuclein and
its dysfunction in disease are both directly linked to the
autophagy/lysosomal pathway is unclear; a recent re-
port suggests an explicit divergence between function
and toxicity (23). However, it is abundantly clear that
this protein is closely linked to autophagy in disease.
GBA
GBA is a lysosomal enzyme that hydrolyzes glucocer-
ebroside, releasing ceramide. Loss-of-function muta-
tions in GBA cause the lysosomal storage disorder GD
in the homozygous state, which leads to an accumula-
tion of glucocerebrosides in the lysosomes. In the
heterozygous state, the same mutations greatly increase
the risk of developing PD (7). What is indisputable is
that mutations in GBA that increase the risk of PD
disrupt lysosomal function, which provides a concrete
link between the synucleinopathy that results from
these mutations and the autophagy/lysosomal pathway.
Altered ceramide levels due to GBA dysfunction can
also affect the Akt and mTORC1 signaling pathways,
altering the autophagy/lysosomal pathway from up-
stream as well as at the point of lysosomal function (24).
LRRK2
LRRK2 is a multidomain enzyme that has been impli-
cated in a large number of cellular processes. An
interaction with membranes and a putative role in the
regulation of autophagy are reoccurring themes in the
LRRK2 literature (5). A number of studies have re-
ported mutations in LRRK2 affecting autophagy via an
as yet unidentified mechanism (25, 26). Also, several
reports suggest that LRRK2 may have a physiological
role in regulating autophagy, with both acute knock-
down and knockout of LRRK2 affecting autophagy.
Mice lacking LRRK2 display alterations in markers of
autophagy and in the lysosomal pathway (27), and
siRNA knockdown of LRRK2 in human cells results in
an increase in the lipid-associated form of the au-
tophagy marker LC3 (25). A recent study reported an
interaction between LRRK2 and CMA, and given the
previously documented link between -synuclein and
CMA, this finding may be of relevance to the accumu-
lation of this protein in the synucleinopathies (28).
These data in toto suggest a close link between LRRK2
and the autophagy/lysosomal pathway.
VPS35 and ATP13a2
Although the neuropathology associated with muta-
tions in VPS35 and ATP13a2 has not been described,
the physiological roles of these proteins place them in
the autophagy/lysosomal pathway.
VPS35 is part of the retromer complex that is in-
volved in the transport of endosomes back to the
trans-Golgi and in the sorting of receptors for hydro-
lases, thus affecting vacuole/lysosomal function and
biogenesis. Loss of function in VPS35 has been shown
to produce vacuolar/lysosomal abnormalities (29).
ATP13a2 is a lysosomal protein, a P5-type ATPase
thought to be responsible for cation transport and the
regulation of manganese levels. Loss of ATP13a2 in
cellular and animal models results in lysosomal dysfunc-
tion, with a reduction in proteolytic activity and accu-
mulation of lysosomes and autophagosomes (30, 31).
The phenotypic spectrum for mutations at the ATP13a2
locus also includes neuronal ceroid lipofuscinosis, a
lysosomal disorder (32).
JOINING THE DOTS
As described above, each of the genes conclusively
linked to inherited synucleinopathy has also been
linked to either lysosomal function or autophagy. Two
further genes linked to parkinsonian syndromes of
LRRK2
GBA
ATP13a2
VPS35
Location: Lysosomes
Physiology: Hydrolase
Location: Unknown
Physiology: Unknown
Location: Endosomes
Physiology: Retromer 
complex
Location: Lysosomes
Physiology: Ion transporter ?
α synuclein
Location: Membranes
Physiology: SNARE biology
Figure 1. Links between the genetic synucle-
inopathies. Venn diagram illustrating the over-
laps between the key genes discussed in this
review and their physiological roles. Solid ar-
rows indicate reported biological interactions,
dotted arrow represents untested interaction.
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undetermined neuropathological status display clear
links to these pathways. What evidence suggests that
these genes are linked and that mutations in them may
have a common effect on the autophagy/lysosomal
pathway?
A number of recent studies have highlighted a recip-
rocal relationship between -synuclein and GBA. A
study by Cullen et al. (33) examined the effect of
mutations in GBA on -synuclein, observing a marked
increase in synuclein levels in the presence of disease
associated mutants. Mazzulli et al. (34) demonstrated
that a decrease in GBA activity results in a preferential
increase in -synuclein levels due to reduced lysosomal
proteolysis. This study also reported that increased
-synuclein levels had an effect on the trafficking of
GBA to the lysosomes, creating a positive feedback
loop. The exact mechanics of the relationship between
-synuclein and GBA are not clear; however, some
evidence supports a direct interaction between these
two proteins (35).
The nature of the interaction between -synuclein
and LRRK2 is a matter of greater conjecture. Several
lines of evidence suggest crosstalk between these pro-
teins, leading to neurodegeneration and PD. A study by
Lin et al. (36) using a combination of mice transgenic
for LRRK2 and -synuclein, as well as LRRK2-knockout
mice, demonstrated that LRRK2 has a major effect on
synuclein neuropathology. Several studies of LRRK2-
knockout mice have observed accumulation of -sy-
nuclein, albeit in the kidneys of these mice rather than
their brains (27). A connection between LRRK2, CMA,
and -synuclein has also been reported (28). Whether
these data reflect a direct interaction between synuclein
and LRRK2, mediated by a LRRK2-dependent phos-
phorylation event or a more distant relationship with
Figure 2. Autophagy/lysosomal pathways to PD: hypothetical framework for the interaction of the genes implicated in the
genetic synucleopathies at the convergence of the autophagy and lysosomal pathways showing location of the genes discussed
in the text.
TABLE 2. Tests of this hypothesis
Experimental test Expected outcome
Neuropathological examination of ATP13a2 and VPS35
mutation carriers
Cases manifesting with extensive LB pathology
Parallel analysis of autophagic flux and lysosomal function in
cellular models for mutated genes
A consistent effect of mutations, pushing these pathways
in a similar direction
Investigating autophagy/lysosomal markers in the brains of
sporadic cases of Parkinson’s disease
Alterations in markers congruent with those observed in
familial forms of disease
Examination of models for disorders where LBs are a
secondary lesion, such as Alzheimer’s disease
Disruption of autophagic/lysosomal pathways as a
secondary effect of the primary pathology
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LRRK2 acting upstream of -synuclein, remains an area
of intense investigation (5).
Several studies link loss of ATP13a2 function to the
accumulation of -synuclein. Both knockout and knock-
down of ATP13a2 result in an accumulation of insolu-
ble -synuclein, as well as neuronal toxicity (37–39).
Very little has been reported regarding the effect of
mutations in VPS35. Macleod et al. (40) report a link
between dysfunction of LRRK2, VPS35, and a locus
recently identified by the genome wide association
study (GWAS) for PD: the PARK16 locus. The research-
ers report that manipulating LRRK2 and a candidate
gene for the PARK16 locus, RAB7L1, results in changes
in endosomal trafficking, linking to the previously
reported function of VPS35 (40).
Somewhat distinct from the familial and genetic
forms of disease under examination here, two novel
mouse models of neurodegeneration have been re-
ported where disruption of a key protein in the au-
tophagy pathway (Atg7) results in accumulation of
-synuclein and LRRK2 (41, 42). These data suggest
that, in addition to an effect on autophagy resulting
from alteration in the function of LRRK2 and -sy-
nuclein, a reciprocal relationship exists between the
physiological process of autophagy and these patholog-
ically linked proteins. A summary of these relationships
is displayed in Fig. 1.
CONCLUSIONS AND TESTS
The data considered in the present work support a
central role for the autophagy/lysosomal pathway in
the pathogenesis of the genetic synucleinopathies, a
possibility that has important ramifications for our
understanding of the pathways that lead to Parkinson’s.
Understanding these pathways is the key to the devel-
opment of new strategies to target a disease that is of
growing importance to health care systems across the
globe. We propose that disorders connected to altera-
tions in SNCA, LRRK2, and GBA, as well as disease
caused by mutations in ATP13a2 and VPS35, can all be
mechanistically linked to the autophagy/lysosomal
pathway (Fig. 2). Key experimental tests of our hypoth-
esis are summarized in Table 2. Our prediction is that
a common theme in the nature of the disruption of
these pathways for each of the mutant genes under
consideration here will emerge, in all cases resulting in
an alteration in the biology of -synuclein. As with any
hypothetical model, it is important to highlight data
that are not consistent with these predictions. Why, for
example, are there LRRK2 mutation carriers who pres-
ent with PD in the absence of LBs? Where do the rare
cases of PARK2 with LBs fit into this scheme? Another
important consideration is whether this model can (or
should) be applied to the sporadic synucleinopathies;
the evidence in the literature that this may be the case
is unclear (43, 44). In common with many neurodegen-
erative disorders, substantial gaps remain in our under-
standing of PD, both inherited and idiopathic. Re-
search over the coming years will provide answers to
some of the questions posed above and, it is to be
hoped, allow us to judge whether the autophagy/
lysosomal pathway does indeed occupy a central role in
the inherited synucleinopathies.
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